A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Launched by BOEHRINGER INGELHEIM · May 21, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for heart failure. Specifically, it aims to find out if a medication called BI 690517, when taken together with empagliflozin, can help improve symptoms in adults aged 18 and older who have heart failure. To join the study, participants should have a specific type of heart failure, known as reduced ejection fraction, with at least 40% heart function. They will be randomly assigned to one of two groups: one group will receive the combination of BI 690517 and empagliflozin, while the other group will receive a placebo (a dummy pill) along with empagliflozin.
Participants can stay in the study as long as the treatment is helping them and they can handle it. Throughout the trial, they will have regular check-ups with their doctors to monitor their health and any side effects. The study does not have a set end date; it will continue until enough information is gathered to determine if the treatment is effective. If you or someone you know has heart failure and meets the eligibility criteria, it might be an opportunity to contribute to important research while receiving care.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. At least 18 years old and at least of the legal age of consent in countries where it is greater than 18 years
- • 2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
- • 3. Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
- • 4. Chronic Heart failure (HF) diagnosed at least 3 months before Visit 1, and in New York Heart Association (NYHA) class II-IV at Visit 1, with left ventricular ejection fraction (LVEF) ≥40% per local reading. A historical LVEF may be used if it was measured within 12 months prior to Visit 1, or the LVEF may be measured after study consent has been obtained and before randomisation at Visit 2
- • 5. Presence of structural heart abnormality (confirmed by any imaging modality; i.e. echocardiography at Visit 1, as defined by left ventricular hypertrophy or left atrial enlargement). Historical imaging may be used if performed within 12 months prior to Visit 1, or imaging may be completed after study consent has been obtained and before Visit 2
- 6. Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) at Visit 1, analysed at the central laboratory at Visit 1:
- • 1. in participants with body mass index (BMI) \<27 kg/m²: ≥300 pg/mL for participants without atrial fibrillation (Afib) or atrial flutter (Aflutter) (at Visit 1 electrocardiogram (ECG)) and ≥900 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
- • 2. in participants with BMI ≥27 kg/m² to \<35 kg/m²: ≥220 pg/mL for participants without Afib or Aflutter (at Visit 1 ECG) and ≥660 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
- • 3. in participants with BMI ≥35 kg/m²: ≥125 pg/mL for participants without Afib or Aflutter (at Visit 1 ECG) and ≥375 pg/mL for participants with Afib or Aflutter (at Visit 1 ECG)
- 7. At least one of the following:
- • Currently treated with diuretic therapy e.g. loop diuretics or thiazides, and on a stable dose for at least 1 week prior to Visit 1
- • Documented hospitalisation for HF within 6 months prior to Visit 1
- • Elevated NT-proBNP at Visit 1, analysed at the central laboratory at Visit 1
- • in participants without Afib or Aflutter (at Visit 1 ECG): ≥900 pg/mL
- • for participants with Afib or Aflutter (at Visit 1 ECG): ≥1800 pg/mL
- • Urine albumin-to-creatinine ratio (UACR) ≥30 mg/g, analysed at the central laboratory at Visit 1
- • 8. Treated according to best possible standard of care (SOC) (disregarding Sodium-dependent glucose co-transporter 2 inhibitors (SGLT2is) and Mineralocorticoid receptor antagonists (MRAs)) in accordance with applicable HF local/international guidelines and judgment of the investigator Further inclusion criteria apply.
- Exclusion criteria:
- • 1. Treatment with an mineralocorticoid receptor antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone) within 14 days prior to Visit 1 or requiring such treatment before randomisation or planned during the trial based on the judgment of the investigator. Treatment with MRA should not be interrupted with the intention of enrolment into the study
- • 2. Treatment with amiloride, or other potassium-sparing diuretic within 14 days prior to Visit 1 or requiring such treatment before randomisation or planned during the trial based on the judgment of the investigator
- 3. Receiving the following treatments:
- • a direct renin inhibitor (e.g. aliskiren) at Visit 2
- • more than one angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI) used simultaneously at Visit 2
- * In case of acute decompensated HF:
- • i.v. inotrope, i.v. vasodilating drug (e.g. nitrate, nitroprusside), or i.v. natriuretic peptide (e.g. nesiritide, carperitide), or mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, any ventricular assist device) within 24 hours prior to randomisation (Visit 2)
- • i.v. diuretic with a dose that has been increased/intensified within 6 hours prior to randomisation (a stable dose of an i.v. diuretic is not exclusionary)
- • Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) at Visit 2
- • Other aldosterone synthase inhibitors, e.g. baxdrostat at Visit 2 or planned during the trial
- • 4. Myocardial infarction (MI), transient ischemic attack (TIA), stroke, coronary artery bypass graft (CABG) surgery, heart valve surgery/intervention or any other major surgery (major according to the investigator's assessment) within 90 days prior to Visit 2, or scheduled for major elective surgery (e.g. hip replacement, coronary artery bypass graft surgery/CABG)
- • 5. Percutaneous coronary intervention (PCI) ( scheduled or unscheduled) or any angiography using iodinated contrast agents in the 7 days prior to Visit 2
- • 6. Heart transplant recipient, awaiting heart transplant, or currently implanted left ventricular assist device (LVAD)
- • 7. Known cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic obstructive cardiomyopathy or genetic hypertrophic cardiomyopathy,known pericardial constriction, or cardiomyopathy with potentially reversible cause such as stress or peripartum cardiomyopathy or cardiomyopathy induced by chemotherapy within the 12 months prior to Visit 1 and until Visit 2
- • 8. Acute inflammatory heart disease, such as acute myocarditis, within the 90 days preceding prior to Visit 1 and until Visit 2
- • 9. Known severe valvular heart disease (obstructive or regurgitant), as per investigator's judgment, or valvular heart disease scheduled for surgical or invasive procedures at Visit 1, or anticipated invasive treatment during the study Further exclusion criteria apply.
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Norfolk, Virginia, United States
Seattle, Washington, United States
Minneapolis, Minnesota, United States
Dallas, Texas, United States
Ocala, Florida, United States
Coeur D'alene, Idaho, United States
Madrid, , Spain
Truro, , United Kingdom
London, , United Kingdom
Munster, Indiana, United States
Tustin, California, United States
Longview, Texas, United States
Clearwater, Florida, United States
Brandon, Florida, United States
Jacksonville, Florida, United States
Orange, California, United States
Mobile, Alabama, United States
Slidell, Louisiana, United States
San Dimas, California, United States
Hammond, Louisiana, United States
Wellington, Florida, United States
North Kansas City, Missouri, United States
Falls Church, Virginia, United States
Miramar Beach, Florida, United States
Arlington Heights, Illinois, United States
West Des Moines, Iowa, United States
Bossier City, Louisiana, United States
Manalapan, New Jersey, United States
Bronx, New York, United States
Kingwood, Texas, United States
Winchester, Virginia, United States
Waukesha, Wisconsin, United States
Naples, Florida, United States
Oldham, , United Kingdom
Dallas, Texas, United States
Papenburg, , Germany
Bridgewater, New Jersey, United States
Lodz, , Poland
Shreveport, Louisiana, United States
Richmond, Indiana, United States
Bad Friedrichshall, , Germany
Ishikawa, Kanazawa, , Japan
Atlanta, Georgia, United States
Saint Louis, Missouri, United States
Jacksonville, Florida, United States
Boca Raton, Florida, United States
Jacksonville, Florida, United States
Fort Worth, Texas, United States
Indianapolis, Indiana, United States
Ciudad Autonoma Buenos Aires, , Argentina
Greenfield Park, Quebec, Canada
Lüneburg, , Germany
Aichi, Kasugai, , Japan
Chiba, Chiba, , Japan
Siedlce, , Poland
Towson, Maryland, United States
Oshawa, Ontario, Canada
Ypsilanti, Michigan, United States
Sofia, , Bulgaria
Chuo Ku, , Japan
Saint Augustine, Florida, United States
Mississauga, Ontario, Canada
Mckinney, Texas, United States
Winter Park, Florida, United States
Boca Raton, Florida, United States
Rapid City, South Dakota, United States
Mckinney, Texas, United States
Daytona Beach, Florida, United States
Amarillo, Texas, United States
Greensboro, North Carolina, United States
Hallandale Beach, Florida, United States
Pleven, , Bulgaria
Greenville, South Carolina, United States
Tokushima, , Japan
Chula Vista, California, United States
Largo, Florida, United States
Dallas, Texas, United States
Frankfurt, , Germany
Johns Creek, Georgia, United States
Olsztyn, , Poland
Sofia, , Bulgaria
Merrillville, Indiana, United States
Ocala, Florida, United States
Port Charlotte, Florida, United States
Marion, Ohio, United States
Jackson, Tennessee, United States
Mobile, Alabama, United States
Libertyville, Illinois, United States
Park Ridge, Illinois, United States
Wichita, Kansas, United States
Dearborn, Michigan, United States
Lincoln, Nebraska, United States
Amarillo, Texas, United States
Valencia, California, United States
Wesley Chapel, Florida, United States
Jefferson City, Tennessee, United States
Mito Shi, , Japan
Edmonton, , Canada
Kobe Shi, , Japan
Lansing, Michigan, United States
Hamada Shi, , Japan
Madison, Wisconsin, United States
Pleven, , Bulgaria
Pleven, , Bulgaria
Stara Zagora, , Bulgaria
Sarnia, Ontario, Canada
Stoney Creek, Ontario, Canada
St. Jean Sur Richelieu, , Canada
Brandys Nad Labem, , Czechia
Prague 10, , Czechia
Smirice, , Czechia
Berlin, , Germany
Budapest, , Hungary
Azumino Shi, , Japan
Higashiibaraki Gun, , Japan
Kamakura Shi, , Japan
Kanagawa, Yokohama, , Japan
Okayama Shi, , Japan
Saitama Shi, , Japan
Gdynia, , Poland
Kraków, , Poland
Iasi, , Romania
Somerset, New Jersey, United States
Butler, Pennsylvania, United States
Chicago, Illinois, United States
Ciudad Autonoma Buenos Aires, , Argentina
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0